Design considerations for efficient prostate cancer chemoprevention trials
- 1 April 2001
- Vol. 57 (4) , 205-212
- https://doi.org/10.1016/s0090-4295(00)00976-6
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Baseline Characteristics of Participants in the Women's Health StudyJournal of Women's Health & Gender-Based Medicine, 2000
- Highlights from recent National Surgical Adjuvant Breast and Bowel Project studies in the treatment and prevention of breast cancerCA: A Cancer Journal for Clinicians, 1999
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI Journal of the National Cancer Institute, 1998
- Development of a decision-making tool to predict risk of prostate cancer: The cancer of the prostate risk index (CAPRI) testUrology, 1997
- Chemoprevention of prostate cancer: The prostate cancer prevention trialThe Prostate, 1997
- Risk Factors for Lung Cancer and for Intervention Effects in CARET, the Beta-Carotene and Retinol Efficacy TrialJNCI Journal of the National Cancer Institute, 1996
- Lack of Effect of Long-Term Supplementation with Beta Carotene on the Incidence of Malignant Neoplasms and Cardiovascular DiseaseNew England Journal of Medicine, 1996
- The Effect of Vitamin E and Beta Carotene on the Incidence of Lung Cancer and Other Cancers in Male SmokersNew England Journal of Medicine, 1994
- Nutrition Intervention Trials in Linxian, China: Supplementation With Specific Vitamin/Mineral Combinations, Cancer Incidence, and Disease-Specific Mortality in the General PopulationJNCI Journal of the National Cancer Institute, 1993
- Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined AnnuallyJNCI Journal of the National Cancer Institute, 1989